Zivo Bioscience Inc's Business Segments

We were incorporated under the laws of the State of Nevada on March 28, 1983, under the name of “L. Peck Enterprises, Inc.” On May 27, 1999, we changed our name to “Western Glory Hole, Inc.” From 1990 until October 2003, we had no business operations; we were in the development stage and were seeking profitable business opportunities. On October 30, 2003, we acquired 100% of the outstanding shares of Health Enhancement Corporation (“HEC”) in exchange for 9,000,000 of our shares, making HEC our wholly-owned subsidiary. In connection with this transaction, we changed our name to Health Enhancement Products, Inc. On October 14, 2014, at the annual meeting of the Shareholders of the Company, a proposal was passed to change the name of the Company from Health Enhancement Products, Inc. to Zivo Bioscience, Inc. (“ZIVO”). On October 30, 2014, the Financial Industry Regulatory Authority (“FINRA”) approved the name Zivo Bioscience, Inc. for trading purposes and the symbol change to ZIVO effective November 10, 2014.

We acquired HEC in 2003 because we believed its unique and complex algal culture produced natural bioactive compounds that promoted health benefits. A production facility based in Scottsdale, AZ produced and marketed a liquid dietary supplement with marginal success beginning in 2003 until sales were suspended in January of 2012.

Our new management team, in place since December 2011, determined the sole focus for the near term was to move forward with a research-based product development program. From 2012 through 2015, we engaged fully in such activities, all as more fully explained herein. We are implementing a business model in which we would derive future income from licensing and selling natural bioactive ingredients that may be derived from or are initially based on the algae cultures. We expect that these planned new products will likely be sold to much larger, better-financed animal, food, dietary supplement and medical food manufacturers. The anticipated income streams are to be generated from a) royalties and advances for licensed natural bioactive ingredients, and b) bulk sales of such ingredients. These bulk ingredients will likely be made by contracted ingredient manufacturers and then sold by us to animal food, dietary supplement and medical food processors and/or name-brand marketers. Further, we expect to license our bioactive molecules as lead compounds or templates for synthetic variants intended for therapeutic applications.

In January 2007, we established HEPI Pharmaceuticals, Inc. as our wholly owned subsidiary (“HEPI Pharma”). The purpose of HEPI Pharma was to develop potential pharmaceutical applications for the bioactive ingredients that may be derived from our algae cultures.

In February 2013, we formed Zivo Biologic, Inc., a Delaware corporation, for the purpose of manufacturing and commercialization of proprietary ingredients for non-medicinal animal health applications. Zivo Biologic is 100% owned by Health Enhancement Products, Inc.

In August 2013, we acquired the assets, consisting primarily of intellectual property rights, of Wellness Indicators, Inc. (“Wellness”), a Michigan corporation based in Illinois. Concurrently, we formed WellMetris, LLC (“WellMetris”) as a 100% owned entity of ZIVO. We acquired four patent applications as part of the transaction, in addition to engineering drawings, prototypes, chemical formulae, validation data, laboratory equipment and IT equipment. We assigned all of the intellectual property acquired to WellMetris with a stated value of $1,391,281. The mission of WellMetris is to develop, manufacture, market and sell Wellness Tests. The Wellness Tests are intended to provide individuals the information and opportunity to optimize their health and identify future health risks or to provide insurers, employers and healthcare providers timely information to intervene with wellness programs, fitness regimes or other preventative measures. During the period of time since we have owned WellMetris, we have filed / drafted an additional eight patent applications around the intellectual property acquired, as noted in the section “Patents and Proprietary Rights.” In the summer of 2014, we evaluated the circumstances related to the original four patent applications acquired and determined that that two of the existing patent applications could be improved and filed new patents applications to redefine and better protect our intellectual property than the original purchased patent applications.

Zivo Bioscience Inc. is focused on developing a range of innovative products and services primarily derived from its unique algal cultures. The company is actively pursuing multiple market verticals, particularly in the areas of animal health, functional foods, dietary supplements, medicinal foods, pharmaceuticals, and health assessment technology. Below is an extensive description of the segments, products, and services that Zivo Bioscience Inc. is working on:

1. Animal Supplements
Zivo Bioscience has developed algal cultures shown to have potential benefits in animal health, particularly for livestock:

- Bovine Mastitis Treatment: The company’s algal culture has demonstrated efficacy in reducing the onset and symptoms of bovine mastitis, a significant condition affecting dairy cows, which can halt milk production and cost dairy farmers substantial financial losses. Initial studies suggest that the algal compounds may restore the immunological barrier of mammary epithelial cells, offering a promising approach to combat this problem.

- Collaboration with Zoetis: Zivo has entered into a collaboration agreement with Zoetis, a global leader in animal health, to further explore the prevention and management of bovine mastitis. The agreement allows for exclusive negotiations regarding a licensing agreement based on the outcomes of joint research.

- Other Livestock Applications: The company aims to create an algal feed ingredient for livestock and expand into global markets with dietary supplements. It also considers licensing isolated bioactive molecules to pharmaceutical companies for synthetic drug development aimed at production animals.

- Bovine Respiratory Disease Complex (BRDC): Research indicates that the same algal compounds that may help with mastitis could also be beneficial in combatting BRDC, commonly known as shipping fever,which affects cattle during transportation from ranches to feedlots.

- Canine Joint Health: Zivo has explored the use of its algal culture in alleviating osteoarthritis symptoms in dogs. Studies indicate potential effectiveness in protecting joint tissues from inflammation and degeneration. The company is looking into bringing this product to market as a companion animal dietary supplement.

Functional Food Ingredients
Zivo intends to penetrate the functional food market with health-promoting ingredients derived from its algal cultures:

- Cholesterol and Immune Response Ingredients: The company is working on developing ingredients that can help support healthy cholesterol levels and enhance immune response. This segment targets a rapidly growing market, as functional foods represent significant revenue opportunities in North America and Europe.

Dietary Supplements and Nutraceuticals
Zivo aims to tap into the large dietary supplement market:

- Private-Labeling Strategy: Instead of branding its products, Zivo intends to partner with established marketers and retailers to private-label its bioactive compounds. This approach is expected to be a more efficient way to monetize its products while retaining intellectual property and control over the manufacturing process.

Medicinal Foods
The company sees potential in the medicinal foods sector:

- Prescription for Specific Uses: Zivo is exploring the viability of its algal extracts being prescribed as medicinal foods to be used during or after medical procedures. This area has less stringent regulatory requirements compared to pharmaceuticals, making it an attractive market.

- Gelatin-Based Delivery System: An innovative product utilizing extracted algal carrageenan has been developed, which could serve as a novel delivery method for medications and supplements, particularly for individuals who may have difficulty swallowing pills.

Pharmaceuticals
Zivo is contemplating the long-term goal of entering the pharmaceutical market:

- Prescription Drug Development: With a focus on the prescription drug application for its bioactive compounds, the company recognizes that this process is complex and requires significant investment and collaboration with co-developers to mitigate risks and share costs.

WellMetris Health Assessment Technology
Zivo has created WellMetris to develop health and wellness testing solutions:

- Phase One Tests: These initial tests assess biomarkers related to oxidative stress, inflammation, and overall metabolic health. They are designed to help both individuals and healthcare providers understand health risks and optimize personal wellness.

- Additional Testing Phases: Subsequent phases aim to measure metabolic responses to dietary changes and provide comprehensive metabolic profiles through urine metabolite analysis. This testing is intended for both human and animal use.

Through these segments, Zivo Bioscience Inc. is positioning itself as a leader in the application of its algal cultures across various health and wellness industries. Each product and area of focus is built on rigorous scientific research and aims to address specific health challenges among both animals and humans. As development progresses, the research is subject to regulatory processes to ensure compliance and market readiness.